oru.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients
Dept Haematol, Karolinska Univ Hosp, Stockholm, Sweden.
M D Anderson Canc Ctr, Univ Texas, Houston TX, USA; Canc Therapy Res Ctr, San Antonio TX, USA.
Fac Hosp Brno, Dept Internal Med Haematooncol, University Hospital, Brno, Czech Republic.
Johannes Gutenberg Univ, Mainz, Germany.
Visa övriga samt affilieringar
2015 (Engelska)Ingår i: British Journal of Haematology, ISSN 0007-1048, E-ISSN 1365-2141, Vol. 170, nr 1, s. 40-49Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

There are limited data on retreatment with monoclonal antibodies (mAb) in patients with chronic lymphocytic leukaemia (CLL). In a pivotal study, ofatumumab (human anti-CD20 mAb) monotherapy demonstrated a 47% objective response rate (ORR) in fludarabine refractory CLL patients. From this study, a subset of 29 patients who had at least stable disease and then progressed were retreated with eight weekly ofatumumab infusions (induction treatment period), followed by monthly infusions for up to 2years (maintenance treatment period). The ORR after 8weeks of induction retreatment was 45% and 24% had continued disease control after maintenance at 52weeks. Efficacy and safety of the retreated patients were compared with their initial results in the pivotal study. Response duration was 241months vs. 68months; time to next therapy was 148months vs. 123months; and progression-free survival was 74months vs. 79months (medians). Upon retreatment, 72% had infusion reactions, mostly Grade 1-2. Three patients had fatal infections. In summary, ofatumumab retreatment and maintenance therapy was feasible in patients with heavily pretreated CLL and appeared to result in more durable disease control than initial ofatumumab treatment in this subset of patients who may have a more favourable disease profile.

Ort, förlag, år, upplaga, sidor
2015. Vol. 170, nr 1, s. 40-49
Nyckelord [en]
ofatumumab, chronic lymphocytic leukaemia, anti-CD20 monoclonal antibody, retreatment, maintenance
Nationell ämneskategori
Hematologi
Identifikatorer
URN: urn:nbn:se:oru:diva-56556DOI: 10.1111/bjh.13380ISI: 000356716500007PubMedID: 25825041OAI: oai:DiVA.org:oru-56556DiVA, id: diva2:1082774
Tillgänglig från: 2017-03-17 Skapad: 2017-03-17 Senast uppdaterad: 2018-07-08Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextPubMed

Sök vidare i DiVA

Av författaren/redaktören
Kozlowski, PiotrRizzi, RitaDyer, Martin J. S.
Av organisationen
Region Örebro län
I samma tidskrift
British Journal of Haematology
Hematologi

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 3 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf